Last reviewed · How we verify

Abrocitinib Suspension F4 (abrocitinib-suspension-f4)

Pfizer Inc. · Phase 1 active Quality 5/100

Abrocitinib Suspension F4 (generic name: abrocitinib-suspension-f4) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.

At a glance

Generic nameabrocitinib-suspension-f4
SponsorPfizer Inc.
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abrocitinib Suspension F4

What is Abrocitinib Suspension F4?

Abrocitinib Suspension F4 (abrocitinib-suspension-f4) is a pharmaceutical drug developed by Pfizer Inc..

Who makes Abrocitinib Suspension F4?

Abrocitinib Suspension F4 is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Abrocitinib Suspension F4?

abrocitinib-suspension-f4 is the generic (nonproprietary) name of Abrocitinib Suspension F4.

What development phase is Abrocitinib Suspension F4 in?

Abrocitinib Suspension F4 is in Phase 1.

What are the side effects of Abrocitinib Suspension F4?

Common side effects of Abrocitinib Suspension F4 include Nausea, Incision site complication, Headache, Dyspepsia, Vomiting, Hunger.

Related